Printer Friendly

i"?Nordion signs agreement with Navidea Biopharmaceuticals.

M2 EQUITYBITES-May 16, 2013-i" Nordion signs agreement with Navidea Biopharmaceuticals(C)2013 M2 COMMUNICATIONS

Nordion, a global health science company, has signed a contract manufacturing agreement with Navidea Biopharmaceuticals, a company focused on the development and commercialisation of diagnostic and radiopharmaceutical imaging agents for cancer and other diseases.

It was reported yesterday that the contract has been signed for NAV5001, a diagnostic imaging agent utilised to detect Parkinsonian Syndromes and Dementia with Lewy Bodies. NAV5001 manufacturing will help Navidea's Phase 2b and Phase 3 trials, scheduled to start in 2013.

The terms of the contract include two phases, a facility preparation and readiness phase and a clinical trial supply phase.

((Comments on this story may be sent to

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 16, 2013
Previous Article:Primco Management unveils JV with Phoenix 51.
Next Article:Hargreaves buys Aardvark operations for GBP10.4m.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters